KITE PHARMA INC's ticker is KITE and the CUSIP is 49803L109. A total of 227 filers reported holding KITE PHARMA INC in Q2 2017. The put-call ratio across all filers is 0.38 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2017 | $85,494,000 | +80.2% | 475,472 | +3.9% | 0.03% | +68.4% |
| Q2 2017 | $47,449,000 | +46.3% | 457,702 | +10.8% | 0.02% | +46.2% |
| Q1 2017 | $32,427,000 | +109.6% | 413,148 | +19.8% | 0.01% | +85.7% |
| Q4 2016 | $15,469,000 | -13.5% | 345,003 | +7.7% | 0.01% | -22.2% |
| Q3 2016 | $17,887,000 | +13.9% | 320,221 | +2.0% | 0.01% | 0.0% |
| Q2 2016 | $15,703,000 | +21.0% | 314,073 | +11.1% | 0.01% | +28.6% |
| Q1 2016 | $12,983,000 | -21.5% | 282,806 | +5.4% | 0.01% | -22.2% |
| Q4 2015 | $16,540,000 | +22.4% | 268,426 | +10.6% | 0.01% | +12.5% |
| Q3 2015 | $13,512,000 | +106.9% | 242,676 | +126.6% | 0.01% | +100.0% |
| Q2 2015 | $6,530,000 | +36.0% | 107,110 | +28.6% | 0.00% | +33.3% |
| Q1 2015 | $4,803,000 | +21.3% | 83,282 | +21.3% | 0.00% | +50.0% |
| Q4 2014 | $3,958,000 | +248.1% | 68,641 | +72.0% | 0.00% | +100.0% |
| Q3 2014 | $1,137,000 | – | 39,900 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Wildcat Capital Management, LLC | 2,358,084 | $108,260,000 | 37.66% |
| Coastal Bridge Advisors, LLC | 250,040 | $11,479,000 | 8.02% |
| RTW INVESTMENTS, LP | 343,503 | $15,770,000 | 5.72% |
| DSAM Partners (London) Ltd | 256,550 | $11,778,000 | 5.26% |
| Silver Rock Financial LLC | 109,199 | $5,013,000 | 5.09% |
| Casdin Capital, LLC | 75,000 | $3,443,000 | 3.95% |
| EcoR1 Capital, LLC | 150,000 | $6,887,000 | 2.41% |
| Vivo Capital, LLC | 193,193 | $8,869,000 | 2.22% |
| BB BIOTECH AG | 750,000 | $34,433,000 | 1.37% |
| MENORA MIVTACHIM HOLDINGS LTD. | 494,988 | $22,725,000 | 1.36% |